VRCA vs. BDTX, CABA, TSVT, KYTX, SGMT, IVA, RENB, TELO, CRBU, and IZTC
Should you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Black Diamond Therapeutics (BDTX), Cabaletta Bio (CABA), 2seventy bio (TSVT), Kyverna Therapeutics (KYTX), Sagimet Biosciences (SGMT), Inventiva (IVA), Renovaro (RENB), Telomir Pharmaceuticals (TELO), Caribou Biosciences (CRBU), and Invizyne Technologies (IZTC). These companies are all part of the "pharmaceutical products" industry.
Verrica Pharmaceuticals vs.
Verrica Pharmaceuticals (NASDAQ:VRCA) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations.
Black Diamond Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -625.06%. Black Diamond Therapeutics' return on equity of -68.08% beat Verrica Pharmaceuticals' return on equity.
Verrica Pharmaceuticals has higher revenue and earnings than Black Diamond Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Verrica Pharmaceuticals received 116 more outperform votes than Black Diamond Therapeutics when rated by MarketBeat users. However, 69.86% of users gave Black Diamond Therapeutics an outperform vote while only 63.98% of users gave Verrica Pharmaceuticals an outperform vote.
42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 42.6% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 8.9% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Verrica Pharmaceuticals currently has a consensus price target of $9.50, indicating a potential upside of 1,190.59%. Black Diamond Therapeutics has a consensus price target of $15.50, indicating a potential upside of 617.59%. Given Verrica Pharmaceuticals' higher probable upside, research analysts plainly believe Verrica Pharmaceuticals is more favorable than Black Diamond Therapeutics.
Verrica Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.51, indicating that its stock price is 151% more volatile than the S&P 500.
In the previous week, Black Diamond Therapeutics had 2 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 2 mentions for Black Diamond Therapeutics and 0 mentions for Verrica Pharmaceuticals. Black Diamond Therapeutics' average media sentiment score of 1.46 beat Verrica Pharmaceuticals' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.
Summary
Black Diamond Therapeutics beats Verrica Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Verrica Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verrica Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VRCA) was last updated on 2/22/2025 by MarketBeat.com Staff
Free VRCA Stock Alerts